Online citations, reference lists, and bibliographies.

Randomized Phase III Trial To Test Accelerated Versus Standard Fractionation In Combination With Concurrent Cisplatin For Head And Neck Carcinomas In The Radiation Therapy Oncology Group 0129 Trial: Long-term Report Of Efficacy And Toxicity.

Phuc Felix Nguyen-Tan, Qiang Zhang, Kian K. Ang, Randal Weber, David I. Rosenthal, Denis Souliéres, Harold E. Kim, Craig L. Silverman, Adam Raben, Thomas J Galloway, A Bonneau Fortin, Elizabeth Gore, William H. Westra, Christine H. Chung, Richard C Jordan, Maura L. Gillison, M. A. List, Quynh-Thu Le
Published 2014 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE We tested the efficacy and toxicity of cisplatin plus accelerated fractionation with a concomitant boost (AFX-C) versus standard fractionation (SFX) in locally advanced head and neck carcinoma (LA-HNC). PATIENTS AND METHODS Patients had stage III to IV carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Radiation therapy schedules were 70 Gy in 35 fractions over 7 weeks (SFX) or 72 Gy in 42 fractions over 6 weeks (AFX-C). Cisplatin doses were 100 mg/m(2) once every 3 weeks for two (AFX-C) or three (SFX) cycles. Toxicities were scored by using National Cancer Institute Common Toxicity Criteria 2.0 and the Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer criteria. Overall survival (OS) and progression-free survival (PFS) rates were estimated by using the Kaplan-Meier method and were compared by using the one-sided log-rank test. Locoregional failure (LRF) and distant metastasis (DM) rates were estimated by using the cumulative incidence method and Gray's test. RESULTS In all, 721 of 743 patients were analyzable (361, SFX; 360, AFX-C). At a median follow-up of 7.9 years (range, 0.3 to 10.1 years) for 355 surviving patients, no differences were observed in OS (hazard ratio [HR], 0.96; 95% CI, 0.79 to 1.18; P = .37; 8-year survival, 48% v 48%), PFS (HR, 1.02; 95% CI, 0.84 to 1.24; P = .52; 8-year estimate, 42% v 41%), LRF (HR, 1.08; 95% CI, 0.84 to 1.38; P = .78; 8-year estimate, 37% v 39%), or DM (HR, 0.83; 95% CI, 0.56 to 1.24; P = .16; 8-year estimate, 15% v 13%). For oropharyngeal cancer, p16-positive patients had better OS than p16-negative patients (HR, 0.30; 95% CI, 0.21 to 0.42; P < .001; 8-year survival, 70.9% v 30.2%). There were no statistically significant differences in the grade 3 to 5 acute or late toxicities between the two arms and p-16 status. CONCLUSION When combined with cisplatin, AFX-C neither improved outcome nor increased late toxicity in patients with LA-HNC. Long-term high survival rates in p16-positive patients with oropharyngeal cancer support the ongoing efforts to explore deintensification.
This paper references
10.1200/JCO.2005.12.060
Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.
Kian K. Ang (2005)
10.1200/JCO.2007.14.8841
Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis.
Mitchell Machtay (2008)
10.1016/j.radonc.2009.04.014
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.
Jean-Pierre Pignon (2009)
10.1214/aos/1176350951
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
R. Gray (1988)
10.1016/S0140-6736(00)90011-4
Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data
Jp Pignon (2000)
10.1200/JCO.2003.01.008
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
David Adelstein (2003)
10.1016/S1470-2045(09)70023-3
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.
Stefan Michiels (2009)
10.1093/annonc/mdq412
Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study.
Marco Carlo Merlano (2011)
10.1200/JCO.2010.30.6423
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer.
Athanassios Argiris (2010)
10.1200/JCO.2013.31.15_SUPPL.6005
E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC).
Shanthi Marur (2013)
10.1200/JCO.2004.00.1792
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
David G. Pfister (2006)
10.1200/JCO.2010.29.0890
Reply to A. Ocana et al
David J Stewart (2010)
10.1007/978-1-4612-4380-9_37
Regression Models and Life-Tables
David Robert Graham Cox (1972)
10.1200/JCO.2010.28.15_SUPPL.5507
A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome.
Kian K. Ang (2010)
10.1056/NEJM199806183382503
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
David M. Brizel (1998)
10.1200/JCO.2011.29.15_SUPPL.5500
A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC).
K Kian Ang (2011)
10.1016/S1470-2045(11)70346-1
Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.
Jean Henri Bourhis (2012)
10.1016/0360-3016(90)90341-G
Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx.
K Kian Ang (1990)
10.1080/00401706.1982.10487769
The Statistical Analysis of Failure Time Data
John P. Klein (1982)
Evaluation of survival data and two new rank order statistics arising in its consideration.
Nathan Mantel (1966)
10.1200/JCO.2004.12.193
Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.
Pia U. Huguenin (2004)
10.1093/jnci/djn460
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.
J. L. Lefebvre (2009)
10.1056/NEJMoa0912217
Human papillomavirus and survival of patients with oropharyngeal cancer.
K Kian Ang (2010)
10.1002/1097-0142(19901101)66:9<1861::AID-CNCR2820660902>3.0.CO;2-I
Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group study 81-17.
Victor A. Marcial (1990)
10.1056/NEJMoa053422
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
James A. Bonner (2006)
10.1016/0360-3016(95)00060-C
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
James D. Cox (1995)
10.1093/jnci/90.11.824
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Jennifer R Grandis (1998)
10.1016/S0140-6736(06)69121-6
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
Jean Bourhis (2006)
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
10.1016/S0360-3016(00)00663-5
A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003
Karen K. Fu (1999)
10.1056/NEJMoa031317
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Arlene A. Forastiere (2003)
10.1002/SIM.5511
Contrasting treatment‐specific survival using double‐robust estimators
KyungMann Kim (2012)
10.1200/JCO.2009.23.0425
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.
Merrill S. Kies (2010)



This paper is referenced by
10.1016/j.jfma.2016.03.005
Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer.
Hung-Ming Wang (2017)
10.1002/hed.25025
AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma
Cory D Fulcher (2018)
10.3978/j.issn.2305-5839.2015.01.37
The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy.
Randall J. Kimple (2015)
10.1016/j.oraloncology.2015.11.019
Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review.
Myung-Ju Ahn (2016)
10.1007/s10555-017-9686-9
The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma
Nicholas Fung (2017)
10.1634/theoncologist.2017-0015
Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
Petr Szturz (2017)
Topic : State of the Art in the Management of Oral Squamous Cell Carcinoma
Dr. Joaquín J. Cabrera-Rodríguez (2016)
10.1186/s12885-016-2165-9
Impact of postoperative daily image-guided intensity-modulated radiotherapy on overall and local progression-free survival in patients with oral cavity cancer
Chen-Hsi Hsieh (2016)
10.1186/s40064-015-1244-8
Concurrent hyperfractionated chemoradiotherapy for head and neck squamous cell carcinoma: the prognostic impact of the overall treatment time and completion rates of chemotherapy
Masami Fujii (2015)
10.1001/jamaoto.2015.0764
Treatment Outcomes for T4 Oropharyngeal Squamous Cell Carcinoma.
Joseph Zenga (2015)
10.3389/fonc.2020.00761
Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Saskia H Hanemaaijer (2020)
10.1158/1078-0432.CCR-19-3977
Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results
Renata Ferrarotto (2020)
10.1517/14656566.2015.1085507
Pharmacotherapy of head and neck cancer
Tobenna I Nwizu (2015)
10.1016/j.clon.2017.02.003
Hypofractionated Accelerated Chemoradiation for Oropharyngeal Cancer and the 2016 Royal College of Radiologists' Fractionation Guidelines.
Charles Fong (2017)
Improving Therapeutics In Head And Neck Cancer
Cyril S. Gary (2018)
10.1016/j.hoc.2019.07.001
Toward a New Framework for Clinical Radiation Biology.
Henning Willers (2019)
10.1016/j.ijrobp.2018.06.031
Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer.
Sweet Ping Ng (2018)
10.1016/J.CANRAD.2018.06.008
Radiothérapie hypofractionnée des cancers ORL chez le sujet âgé
Cécile Ortholan (2018)
10.3389/fonc.2019.01126
A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study—Part 2 (Radiation Oncology)
Olgun Eliçin (2019)
10.1186/s41199-016-0007-8
Considerations in surgical versus non-surgical management of HPV positive oropharyngeal cancer
Christopher E. Fundakowski (2016)
10.18632/oncotarget.6253
Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential
Luo-dan Zhao (2015)
10.1158/1055-9965.EPI-19-0038
Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States
Brandon A Mahal (2019)
10.1016/j.canrad.2017.07.032
[Radiotherapy for head and neck squamous cell carcinoma: State of the art and future directions].
Ulrike Schick (2017)
Identi fi es a Novel AXL – PI 3 Kinase – PD-L 1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer
Heath D. Skinner (2017)
10.1093/carcin/bgz019
Lymphocyte Telomere Length Predicts Clinical Outcomes of HPV-Positive Oropharyngeal Cancer Patients after Definitive Radiotherapy.
Xiaoning Luo (2019)
10.1016/j.ijrobp.2016.04.030
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
Tanguy Y. Seiwert (2016)
10.1002/hed.24313
Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma.
Min Yao (2016)
10.1016/j.hoc.2015.07.005
Sequential and Concurrent Chemoradiation: State of the Art.
Nicole G. Chau (2015)
10.3389/fonc.2019.00086
Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer
Petr Szturz (2019)
10.1001/jamaoncol.2019.4889
Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer.
Brian C. Baumann (2019)
10.1016/j.oraloncology.2017.08.015
Chemoradiotherapy for locally advanced squamous cell carcinoma of the oropharynx: Does completion of systemic therapy affect outcomes?
Michael J. Baine (2017)
10.1080/00016489.2017.1293295
Efficacy and toxicity profiles of two chemoradiotherapies for stage II laryngeal cancer – a comparison between late course accelerated hyperfractionation (LCAHF) and conventional fractionation (CF)
Eiichiro Okazaki (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar